Trial Profile
A Phase I Trial of BKM120 in Combination With Weekly Nabpaclitaxel (Abraxane) in Patients With Advanced Solid Tumors Followed by a Dose Expansion Phase in Patients With Recurrent Endometrial or Recurrent Ovarian Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Paclitaxel (Primary)
- Indications Endometrial cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- 27 Jul 2022 Planned End Date changed from 1 Feb 2015 to 25 Feb 2015.
- 27 Jul 2022 Planned primary completion date changed from 1 Feb 2015 to 25 Feb 2015.
- 30 Jan 2022 Planned End Date changed from 1 Jul 2017 to 1 Feb 2015.